Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment

Ersilia Varone(Mario Negri Institute for Pharmacological Research), Ester Zito(University of Urbino), Luca Guarrera(Mario Negri Institute for Pharmacological Research), Daniele Generali(University of Trieste), Mario Salmona(Mario Negri Institute for Pharmacological Research), Yvonne Janssen‐Heininger(University of Vermont), Augusto Bleve(Mario Negri Institute for Pharmacological Research), Michele Retini(University of Urbino), Andrea Guidarelli(University of Urbino), Marten Beeg(Mario Negri Institute for Pharmacological Research), Marco Bolis(Unknown), Jaehyung Cho(Washington University in St. Louis), Michele Mari(University of Urbino), Alfredo Cagnotto(Mario Negri Institute for Pharmacological Research), Chiara Grasselli(Mario Negri Institute for Pharmacological Research), Giovanni Bottegoni(University of Urbino), Giovanni Piersanti(University of Urbino), Orazio Cantoni(University of Urbino), Stefano Fumagalli(Mario Negri Institute for Pharmacological Research), Maria Chiara Barbera(Mario Negri Institute for Pharmacological Research), Massimo Broggini(Mario Negri Institute for Pharmacological Research), Alessandro Cherubini(University of Urbino), Manuela Milani(Humanitas University), Marco Gobbi(Mario Negri Institute for Pharmacological Research), Alice Marrazza(University of Urbino), Alexander Chernorudskiy
Cell Death and Disease
February 17, 2025
Cited by 16


Related Papers